Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Zevra Therapeutics is a commercial-stage company focused on impacting individuals with rare diseases [2] - The company is currently in a growth phase, with the operational capacity to pursue its commercial and development goals [2] Product and Revenue - Zevra is commercializing its lead product, MIPLYFFA, in the U.S. for Niemann-Pick disease type C and has an MAA under review by the EMA [3] - The company is expanding access through geographic opportunities and has a pipeline of rare disease programs [3] - In the first nine months of the previous year, Zevra generated net revenues of $72.3 million and ended Q3 with a strong cash position of $230.4 million [3]